Bibliographic Details
| Title: |
Transcatheter Closure of Postoperative Residual Atrial or Ventricular Septal Shunts in Patients with Congenital Heart Disease. |
| Authors: |
Xiao, Jiawang1 (AUTHOR), Wang, Jianming1 (AUTHOR), Wang, Zhongchao1 (AUTHOR), Meng, Lili1 (AUTHOR), Zhao, Ming1 (AUTHOR), Wang, Qiguang1 (AUTHOR) wqg1993@126.com |
| Source: |
Congenital Heart Disease. 2024, Vol. 19 Issue 3, p293-303. 11p. |
| Subject Terms: |
*CONGENITAL heart disease, *SURGICAL anastomosis, *CARDIAC patients, *INFECTIVE endocarditis, *PATIENT safety, *CEREBROSPINAL fluid shunts |
| Abstract: |
Background: Transcatheter closure (TCC) has emerged as the preferred treatment for selected congenital heart disease (CHD). While TCC offers benefits for patients with postoperative residual shunts, understanding its mid- and long-term efficacy and safety remains crucial. Objective: This study aims to assess the mid- and long-term safety and efficacy of TCC for patients with residual atrial or ventricular septal shunts following CHD correction. Methods: In this consecutive retrospective study, we enrolled 35 patients with residual shunt who underwent TCC or surgical repair of CHD between June 2011 to October 2022. TCC candidacy was determined based on established criteria. Echocardiography and electrocardiogram were conducted during the perioperative period and continued as part of long-term follow-up. Results: Among the patients, 5 (14.3%) exhibited interatrial shunting, while 30 (85.7%) had interventricular shunting. TCC was successfully implemented in 33 of 35 patients, with exceptions in two cases of post-ventricular septal defect repair due to anatomical challenges involving the shape and aortic angulation. This resulted in a TCC success rate of 94.3%. Trace residual shunt was detected in two interventricular shunting cases and a mild residual shunt in one interventricular shunting case; all resolved by the three-month follow-up after TCC. Minor complications included one hematoma at the puncture site and one transient junctional rhythm during the perioperative period. During a median follow-up of 73 months, there were no instances of residual shunt, device embolization, occluder displacement, valve insufficiency, malignant arrhythmia, infective endocarditis, death, or other serious complications. Conclusion: TCC is an effective and safe therapy for patients with residual atrial or ventricular septal shunts following CHD correction. These findings support the consideration of TCC as the preferred treatment option for appropriate patient populations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Congenital Heart Disease is the property of Tech Science Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
